Drugs / MPL-SE
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01751048 | Mar 2013 → Jan 2015 | leishmaniasis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00982774 | Apr 2009 → Apr 2011 | cutaneous leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1 | NCT00111514 | Jul 2004 → May 2006 | mucocutaneous leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01011309 | Oct 2009 → May 2011 | cutaneous leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00486382 Background | Apr 2007 → Nov 2008 | visceral leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1 | NCT00121849 Background | Aug 2005 → Feb 2006 | cutaneous leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1 | NCT00111553 Background | Oct 2004 → Aug 2006 | cutaneous leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00121862 Background | Aug 2005 → Mar 2006 | cutaneous leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MPL()-SE | “LEISH-F1+MPL-SE vaccine (consisting of 5, 10, or 20 μg recombinant Leishmania polyprotein LEISH-F1 antigen+25 μg MPL(®)-SE adjuvant)” PMID 20851080 ↗ Sep 2010 |
| Known as | Monophosphoryl Lipid A-Stable oil-in-water emulsion | “Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE) is an oil-in-water emulsion that contains Monophosphoryl Lipid A, an attenuated form of Lipid A from Salmonella...” NCT01751048 ↗ |
| Modality | Other / unclassified | “the adjuvant MPL-SE (25 μg)” NCT00121849 ↗ |
| Route | Subcutaneous | “The study injections were given subcutaneously on Days 0, 28, and 56” PMID 20851080 ↗ Sep 2010 |